FDA Clearance Tracker · K250813
MICROLET®NEXT 2 Lancing Device
Last checked: Nov 20, 2026Latest source record: May 14, 2025 (this decision)Source: openFDAMethods & limitations
Decided
May 14, 2025
Substantially Equivalent
Time to decision
58 days
Received Mar 17, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K250813
- Device name
- MICROLET®NEXT 2 Lancing Device
- Applicant
- Ascensia Diabetes Care U.S., Inc.
- Applicant location
- Parsippany, NJ
- Received
- Mar 17, 2025
- Decided
- May 14, 2025
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 878.4850
- Specialty
- General & Plastic Surgery
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QRL. The earliest in FDA's data is K214022, decided Feb 17, 2022.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K250813
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Ascensia Diabetes Care U.S., Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K241787 · Decided Aug 27, 2024 · 67 days after receipt
Device type: System, Test, Blood Glucose, Over The Counter (NBW) · Laboratory Medicine & Pathology
- MICROLET®NEXT Lancet510(k)
K241810 · Decided Aug 15, 2024 · 55 days after receipt
Device type: Single Use Only Blood Lancet Without An Integral Sharps Injury Prevention Feature (QRK) · General & Plastic Surgery
K223293 · Decided Nov 18, 2022 · 23 days after receipt
Device type: System, Test, Blood Glucose, Over The Counter (NBW) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.